Atea Pharmaceuticals Q4 net loss widens

Atea Pharmaceuticals

05/03/2026 21:29

Overview

Biopharmaceutical firm's Q4 net loss widened to $44.9 mln from $33.5 mln a year ago

Company advancing Phase 3 HCV program, with results expected in 2026

Expanded antiviral pipeline with new HEV program, clinical trials start mid-2026

Outlook

Company anticipates mid-2026 topline results from North American HCV trial

Atea plans to start HEV clinical development mid-2026

Company expects year-end 2026 results from HCV trial outside North America

Result Drivers

R&D EXPENSES - Rose to $47.8 mln from $25.7 mln, partially driven by an increase in external spend for HCV Phase 3 clinical development including the purchase of comparator drug and expense related to the achievement of a milestone under the Merck license agreement

INCOME TAX BENEFIT - Co recorded benefit of $6.8 mln due to recognition of previously unrecognized tax benefits following a lapse in the statute of limitations

Company press release: ID:nGNXkwGB8

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$44.87 mln
Q4 Basic EPS
-$0.57
Q4 Operating Expenses
$54.93 mln
Q4 Operating Income
-$54.93 mln
Q4 Pretax Profit
-$51.64 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Atea Pharmaceuticals Inc is $6.00, about 20.5% above its March 4 closing price of $4.98

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)